Find a Clinical Trial
|Protocol||Trial Name and Objective|
Autophagy and Anti-Angiogenesis in Metastatic Colorectal Carcinoma: A Phase II trial of Hydroxychloroquine to Augment Effectiveness of Chemotherapy and Bevacizumab (AAA-CRC). A Study of the Cancer Institute of New Jersey Oncology Group (CINJOG)
The usual treatment for colon cancer that has recurred (returned) after surgical removal or that has spread beyond where surgery can cure it is chemotherapy. The current standard treatments include chemotherapy plus an antiangiogenesis drug (prevents the growth of cancer blood vessels). The chemotherapy consists of oxaliplatin given intravenously (by vein) and either or capecitabine (oral 5FU) given as pills. The antiangiogenesis drug is bevacizumab given by vein. This therapy shrinks cancer (remission) in about half the patients treated. However, some patients do not get shrinkage or the shrinkage is only temporary. Hydroxychloroquine is an older drug used to treat malaria, which may have new use in cancer to prevent cancer cells from becoming resistant to chemotherapy. The purpose of this study is to try to determine if adding hydroxychloroquine to a standard treatment for colon cancer will allow more patients to have tumor shrinkage or tumor shrinkage for a longer time
BrUOG 276: A Phase I/II Evaluation of ADXS11-001, Mitomycin, 5-fluorouracil (5-FU) and IMRT for Anal Cancer
1) To evaluate the safety of the addition of ADXS11-001 to standard chemoradiation for patients with anal cancer.
PROGNOSTIC FACTORS FOR INCIDENTAL GALLBLADDER CANCER
The goal of this study is to evaluate whether age, sex, presence of inflammation, grade, stage, or inadvertent gallbladder perforation affect survival of patients with incidental gallbladder cancer
Retrospective Comparative Analysis of Hematologic Toxicities in Patients Receiving Chemo-Radiotherapy in Rectal Cancers Versus Chemotherapy in Colon Cancers.
To quantify bone marrow toxicity after radiation therapy in rectal cancer patients compared to bone marrow toxicity without radiation therapy in colon cancer patients.
Analysis of HMGI-C and HMGI-Y expression human benign and malignant tissues
examine the expression profiles of HMGI-C and HMGI-Y proteins in malignant and benign colon tumors.
Couple-Focused Intervention for Colorectal Cancer Screening
Specific Aim 1:To compare the efficacy of three interventions: Enhanced Couple-Tailored Intervention (E-CTI), an Enhanced Couples' Generic Intervention (E-GCI), and a Generic Print Intervention (GP) on couples' CRCS.
Retrospective and Prospective review of Patients with Metastatic colorectal cancer with ≥ 24 month survival
Review the characteristics and the treatment of all patients with metastatic colon cancer who have survived more than two years after diagnosis of metastatic disease.
Improving Patient Access to Quality Cancer Treatment (IMPACT)
Specific Aims for Phase I
Molecular Analysis of Rare Tumors Subclasses
The overall aim is to determine what set of genomic alterations are present in ampullary cancers. If we find that, similar to our index case, activating mutations in tyrosine kinases are present in a significant subset of these cancers, this finding may lead to novel therapeutic strategies for these cancers.
Clinical Evaluation of Molecular Changes Underlying Malignant Progression in Barrett's Esophagus
To develop and validate quantitative RT-PCR, immunohistochemistry and Fluorescent in-situ hybridization (FISH) based diagnostic assays against cytogenetic events that may predict higher risk of development EA in patients with BE.
CALGB C80702: A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer
To compare disease-free survival of patients with stage III colon cancer randomized to standard chemotherapy (FOLFOX) or standard chemotherapy with 3 years of celecoxib 400 mg daily.
Phase IB Study of MK-3475 in Subjects with Select Advanced Solid Tumors
To evaluate preliminary signals of potential anti-tumor activity of MK-3475
DEK-DKK1-P102: A Two Part, Phase 1, Multi-center, Open-label Study of DKN-01 in Combination with Weekly Paclitaxel; Arm A: A Dose-Escalation Study in Patients with Relapsed or Refractory Esophageal Cancer or Gastro-esophageal Junction Tumors; Arm B: An Expansion Cohort in Patients with Relapsed or Refractory Esophageal Cancer or Gastro-esophageal Junction Tumors
CALGB A021202: Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754, IND 75648) Versus Placebo in Patients with Progressive Carcinoid Tumors
Neogenix0901: A Phase 1/2 Therapeutic, Open Label, Multi-Center Clinical Trial of NPC-1C, a Chimeric Monoclonal Antibody in Adults with Recurrent, Locally Advanced Unresectable or Metastatic Pancreatic and Colorectal Cancer after Standard Therapy
Determine the safety and tolerability of escalating doses of NPC-1C (NEO-102) monoclonal antibody therapy in subjects with metastatic, locally advanced unresectable or recurrent pancreatic cancer or metastatic colorectal cancer that express NPC-1C target on tumor;
NCI/CTEP #9571: A Phase IB Study of the Combination of AZD6244 Hydrogen Sulfate (Selumetinic) and Cyclosporin A (CsA) in Patients with Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer
Primary Objective: To determine the maximum tolerated dose (MTD)and dose-limiting toxicities (DLT) of the combination of AZD6244 and cyclosporin A in adult patients with advanced solid tumors.
TO-TAS-102-401: AN OPEN-LABEL EXPANDED ACCESS STUDY OF TAS-102 IN PATIENTS WITH METASTATIC COLORECTAL CANCER REFRACTORY TO OR FAILING STANDARD CHEMOTHERAPY
TO provide access to TAS-102 to patients with metastatic colorectal cancer who are refractory to or failing standard chemotherapy, are new to therapy with TAS-102 and in whom therapy with TAS-102 is clinically indicated, in the time period between completion of the Phase 3 clinical trial protocol TPU-TAS-102-301 and prior to TAS-102 being commercially available. This is an unmet clinical need